



CORPORATE OVERVIEW

Isodiol International, Inc. is a global CBD innovator specializing in the development of pharmaceutical and nutraceutical products.



CONTENTS

- 3 International Growth
- 4 History Timeline
- 6 Key Investment Highlights
- 7 Key Milestones
- 8 Active Pharmaceutical Ingredients
- 9 Bulk CBD Ingredients
- 10 Pain Management
- 11 ISODERM™
- 12 Consumer Products
- 14 Key Members
- 15 Contact



POISED FOR INTERNATIONAL GROWTH AND PHARMACEUTICAL DRUG DEVELOPMENT

Early Stage With Huge Potential

Isodiol's objective is to become the worldwide leader in the development and sales of CBD based pharmaceuticals and consumer wellness products. Its mission is to create a cultural movement by building awareness and social acceptance throughout the world.

Isodiol maintains exclusive and unrestricted access to large scale hemp production capacity and leverages its patented, natural, GMP extraction methods to avoid costly synthetic manufacturing processes. The extracted CBD can be delivered as raw material or formulated into oils, cosmetics, foods and pharmaceutical products.

Globally, legislation is being passed to allow hemp cultivation, production and manufacturing for CBD products. Isodiol is working with local health authorities globally to develop and implement regulatory standards for product quality and has multiple clinical studies and trials being conducted.

HISTORY OF ISODIOL

In 2009, Isodiol began researching medical studies where synthetic cannabidiol (CBD) was successful in treating serious medical conditions like Epilepsy and Meige Syndrome. From 2009–11, Isodiol worked to build a commercially feasible extraction process and supply chain of natural hemp derived CBD.

2013-15: 2 years of clinical studies for CBD Skincare and the development of the CannaCeuticals skincare line.

2009

ISO99™

2011

Cēbidiol™

2012

2013


In 2011, the first manufacturing facility was setup to process pure, natural CBD and ISO99™ CBD™ was born.

Cebidiol™ is developed:
A micro-encapsulation method for CBD was developed for use in skincare and cosmetic products.

1ST CRYSTALLINE CBD MANUFACTURER

1ST WITH ISO9001 AND GMP CERTIFICATION ON PRODUCTION

1ST CRYSTALLINE DERIVED FROM EU CERTIFIED ORGANIC HEMP



1ST TO USE NANO-TECHNOLOGY AND MICRO-ENCAPSULATION

1ST CLINICAL STUDY FOR CBD SKINCARE PRODUCTS

1ST TO FORMULATE CBD INTO BEVERAGES



KEY INVESTMENT HIGHLIGHTS

CSE DATA AS OF 08/10/2018

SYMBOL: **ISOL** (*In Canadian Dollars*) Closing

Price: **\$2.73**

Market Cap: **\$110,044,146**

Total Issued and Outstanding: **\$40,309,211**

Since Being Acquired and Listed On the Canadian Securities Exchange (CSE), Key Milestones and Achievements Include:

Reported audited revenues for the Fiscal Year Ended March 31, 2018 of \$19,137,266 compared to Fiscal Year Ended March 31, 2017 audited revenues of \$355,959; a year-over-year increase of 5276%.

- Signed Definitive Licensing Agreement with Canopy Growth Corporation (WEED:CA) for Company's Pot-O-Coffee and Pot-O-Tea.
- Brazilian Health Regulatory Agency (ANVISA) approval of ISODERM™ and ISODIOLEX™, enabling both to be prescribed by doctors and neurologists for the treatment of Epilepsy and Parkinson's Disease.
- Acquired 99% of Purodiol Do Brasil Ltda (PUR-Brazil). PUR-Brazil supplies Purodiol pharmaceutical products under ANVISA regulations and is currently involved in multiple clinical studies and trials.
- Announced Unaudited May 2018 Revenues of \$3,316,646 CDN
- Announced Binding Agreement to Acquire 51% of Round Mountain Technologies, LLC and Commenced Organic Hemp Farming in Nevada.
- Signed a Licensing Agreement with Livecare Health Canada Inc, granting Isodiol the exclusive right to use Livecare's Telehealth Platform relating to all cannabis, cannabis derived, cannabinoid and phytoceutical products.
- Announced Partnership with Europe's leading MMA promoter, Cage Warriors, through its brand Iso-Sport™.
- Included as a show segment on the national PBS series "American Health Journal – Innovations in Medicine." The featured segment highlights CBD, its benefits in treating neurological conditions and associated pain, as well as a patented drug delivery system.

Completed acquisition of BSPG Labs in the U.K. which produces an MHRA approved Active Pharmaceutical Ingredient (API) and is involved in clinical trials and studies globally.

- Signed Definitive Agreement to acquire premier bottling facility, Azure Bottling LLC, with full capacity running approximately 5.3 million bottles per month.
- Announced Partnership Between ISO-Sport and ALTIS, an Elite Training Environment for Athletes & Coaches home to over 100 athletes and Olympians from 30 different countries.
- Completed Acquisition to acquire 100% of leading specialty vape retailer KURE Corp, a company with unaudited fiscal 2018 revenue of 8.8 million USD. Will begin its first phase of expansion on the west coast with the opening of seven locations in the Greater Phoenix market which are anticipated to grand open in the middle of September.
- Consolidated common shares of the Company at a ratio of one (1) post-consolidated common share for every ten (10) pre-consolidated common shares (the "Consolidation"); reducing the Company's issued and outstanding common shares to approximately 39,580,349.
- The Company's wholly owned subsidiary BSPG Laboratories, LTD. has received government approval from United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA), in accordance with The Human Medicines Regulations 2012 (SI 2012/1916), for the manufacturing of the active substance Cannabidiol (CBD) under certificate number: UK API 48727.




ACTIVE PHARMACEUTICAL INGREDIENTS

For Pharmaceutical Use and Clinical Research

BSPG Laboratories is a manufacturer of clinical stage Cannabidiol located in the United Kingdom that produces a pure, natural CBD molecule, with no traces of THC.

BSPG is registered with the Medicines and Healthcare Products Regulatory Agency's (MHRA) to manufacture an approved pharmaceutical grade ingredient (API). The API approval is for the compound Cannabidiol. This approval confirms the procedures and practices used are pharmaceutical grade and the ingredients manufactured are qualified for use in the manufacturing of therapeutic drugs for Humans, and Veterinarian products.

Any pharmaceutical company developing CBD-based finished pharmaceutical products for humans or animals could source the API from BSPG. Registration with the MHRA has entitled BSPG to supply its isolated CBD to pharma companies in all of the countries that are part of the Mutual Recognition Agreement (MRA), which includes USA, Canada, Australia, EU, etc.



What is an API?

An active pharmaceutical ingredient (API) is a biologically active ingredient used in the fabrication of finished pharmaceutical products (FPP). The facility that manufactures such an API ingredient must be inspected and approved by a regulatory body for their Good Manufacturing Practice (GMP) standards. BSPG has proudly acquired its cGMP certificate.

It's Just Not About One API or Compound

BSPG's capabilities are not limited to CBD alone but can be extended to other Cannabinoid molecules such as THC, CBG, and CBN. All of these molecules are said to have their own distinct therapeutic benefits and potentially larger, if not similar, market valuations.

THE INNOVATING SUPPLIER OF CBD.

Isidiol® offers bulk CBD isolate and full-spectrum CBD oil as well as proprietary delivery methods of CBD that can be easily added to a variety of products and formulations.

Cēbidiol™

NUTRA
99™

BSPG™
CANNABIDIOL

HENEPLEX™



PAIN MANAGEMENT



The Isodiol RAPID PATCH is a fast-acting topical pain relief solution, powered by lidocaine, menthol and ISO99™.

While the lidocaine provides soothing anesthetic properties to calm nerves and stop pain impulses to the brain, Menthol adds analgesic qualities, penetrating deeply to help relieve pain in muscles and tendons.



RAPID COOLING PAIN CREAM™ delivers continual soothing relief for muscles, joints, arthritis, back and knee pain.

Formulated with Bioactive Cebidiol™ and combined with stimulating menthol and eight homeopathic ingredients including lavender, rosemary and other essential oils, this cooling gel is a fast acting topical pain relief solution, ideal for use after strenuous activity.

ISODERM

DIRECT EFFECTS TECHNOLOGY™

ISODERM DIRECT EFFECTS TECHNOLOGY™ delivers ISO99™ CBD directly to the critical area to modulate “Afferent Neural Input” to the brainstem and other CNS structures by application to the back of the neck at the hair line (BONATH™). With ISO99™, ISODERM™ offers the most effective CBD available in the marketplace.



- Applied to skin at the back of the neck at the hairline
- Uses an advanced patented technology called Direct Effects Technology™ to rapidly facilitate the delivery of active ingredients.
- Unique and gentle combination that works without the concerns of systemic side effects and drug interactions commonly encountered with systemic neuroactive compounds.



DOCTOR DEVELOPED


Dr. Ron Aung-Din developed DIRECT EFFECTS TECHNOLOGY™ to help more people find natural relief that may be afforded by phytocannabinoid advancements.

As a neurologist with over 35 years of experience in General Neurology and Neuropsychiatry, Dr. Ron specializes in epilepsy, multiple sclerosis, Alzheimer's Disease, dementia, migraine and tension headaches, and other disorders and diseases affecting the central nervous system.

ISODERM

ADVANCED BY PATENTED
BONATH™ DELIVERY

(Back of the neck at the hairline)



ISODIOL HAS RECEIVED APPROVAL FROM THE BRAZILIAN HEALTH REGULATORY AGENCY (ANVISA) FOR THE APPROVAL OF ITS PHARMACEUTICAL GRADE CANNABIDIOL (CBD) PRODUCT, ISODERM™. THIS PRODUCT IS PLACED ON THE SPECIAL CATEGORY LIST FOR ALTERNATIVE THERAPIES WHICH IS ABLE TO BE PRESCRIBED BY MEDICAL DOCTORS AND NEUROLOGISTS.

ADDITIONAL SUBMISSIONS FOR REGULATORY APPROVAL: MEXICO, CHILE, URUGUAY, PARAGUAY, ARGENTINA, AND OTHER LATIN AMERICAN COUNTRIES.

A collection of Rapid CBD products is displayed. In the foreground, there is a white jar of EASE CAPS (Premium Potent Complex 25mg CBD) and a white tube of RAPID CBD RELIEF CREAM (Fast Pain Relief). Behind them are several white bottles of RAPID CBD MULTI SPECTRUM BLEND (Premium Medicinal Terpene Infused CBD) in 2.5 FL OZ (75mL) and 1.5 FL OZ (45mL) sizes. To the right, there are more bottles of RAPID CBD DEASE (Relax & Ease) and a white jar of RAPID CBD BODY BALM (Body Care Complex 10mg CBD). The products feature the Rapid CBD logo and various product-specific icons like a leaf for EASE and a flower for DEASE.

The image displays four ISO-SPORT products against a dark background. At the top center is a large black bag of **MEND** Joint Pain, Arthritis, Muscle Aches, containing 50MG CBD per bottle, with a cooling pain cream applicator. To the left is a jar of **SOOTHE** Intensive Cream, also with 50MG CBD per jar. In the foreground center is a bottle of **REST** Muscle Recovery Sleep, containing 25MG CBD per capsule. To the right is a spray bottle of **GUARD** Joint Pain Protection, containing 50MG CBD per bottle. All products feature the ISO-SPORT logo and the word 'FORMULA'.

A bag of Light It Up coffee, a box of Light It Up coffee, and a single cup of coffee. The bag and box feature a tropical mountain landscape design. The bag is labeled 'LIGHT IT UP' and 'HANDMADE INFUSED'. The box is also labeled 'LIGHT IT UP' and 'HANDMADE INFUSED'. A single cup of coffee is shown next to the box.

12 | ISODIOL®

BRANDS

kathy ireland[®]
HEALTH & WELLNESS
by ISODIOL[®]

 **ISO-SPORT**[™]
CBD PERFORMANCE PRODUCTS

 **AQUIVITA**

RAPIDCBD

 **exogen**[™]



CannaCeuticals
LUXURY SKIN CARE

CBD  **TREME**

THE ISODIOL TEAM

Key Members

Isodiol has a highly skilled team of Global leaders that are constantly innovating and creating standards for the Industry.

Marcos Agramont, *Chief Executive Officer and Director*

Mr. Agramont has been a leading innovator in the Cannabis Industry for the last five years developing products for domestic and international channels. He has pioneered delivery systems, regulations and processes for major brands in order to meet safety standards and compliance. He was instrumental in implementing innovative delivery apparatuses with concise servings, at a time when no accurate measuring of dosage for general usage existed. Mr. Agramont has helped introduce CBD to the pharmaceutical global markets including Japan, Latin America, the European Union and Australia.

Patrick Ogle, *Chief Operating Officer and Director*

Mr. Ogle is a seasoned general counsel to public companies and has co-founded and operated private businesses in the beverage, staffing, apparel, and mining industries throughout the past twenty years. He began his legal career as a federal judicial law clerk and as an associate in the investment management and capital markets practice groups at a renowned law firm in Washington, D.C. and New York City.

Aman Parmar, *Chairman*

His corporate experience includes twelve years working with both public and private companies in the Health Care, Resource, Manufacturing and Real Estate sectors. Aman has extensive experience in the capital markets and has been involved in corporate restructurings and financings for both public and private companies. He obtained a Chartered Accountant designation in 2012 and holds a Bachelor of Technology in Accounting from the British Columbia Institute of Technology.

Eli Dusenbury, *CFO*

Eli has 8 years of public accounting experience providing financial reporting, operational and assurance engagement services to a variety of both public and private sector entities reporting in Canada and the US.

Dr. Ronald Aung-Din, *Medical Advisor and Inventor of Direct Effects Technology*




Dr Aung-Din, MD, practices General Neurology and Neuropsychiatry in Sarasota, FL. In 2009, Dr. Aung-Din founded AfGin Pharma, LLC, a research and development biopharmaceutical company dedicated to Direct Effects Topical Neuro-Affective Therapy. To date, 7 patents relating to the technology have been granted by USPTS and the EU and Australian patent offices.



@isodiol

CORPORATE DIRECTORY

Investor Contact

 **Mike Parmar**
 +1-604-409-4409
 mikeparmar@isodiol.com

Stock Symbols:

CSE: ISOL
OTC: ISOLF
GERMANY: LB6A.F



+1 855.979.675 | www.isodiol.com

CSE: ISOL | **OTC:** ISOLF | **GERMANY:** LB6A.F